156 related articles for article (PubMed ID: 11276802)
1. Use of the ACCES model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway.
Svarvar P; Aly A
Rheumatology (Oxford); 2000 Dec; 39 Suppl 2():43-50. PubMed ID: 11276802
[TBL] [Abstract][Full Text] [Related]
2. The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis.
Haglund U; Svarvar P
Rheumatology (Oxford); 2000 Dec; 39 Suppl 2():51-6. PubMed ID: 11276803
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.
Bessette L; Risebrough N; Mittmann N; Roussy JP; Ho J; Zlateva G
J Med Econ; 2009 Sep; 12(3):246-58. PubMed ID: 19743942
[TBL] [Abstract][Full Text] [Related]
4. Overview of the arthritis Cost Consequence Evaluation System (ACCES): a pharmacoeconomic model for celecoxib.
Pettitt D; Goldstein JL; McGuire A; Schwartz JS; Burke T; Maniadakis N
Rheumatology (Oxford); 2000 Dec; 39 Suppl 2():33-42; discussion 57-9. PubMed ID: 11276801
[TBL] [Abstract][Full Text] [Related]
5. Economic outcomes for celecoxib: a systematic review of pharmacoeconomic studies.
Huelin R; Pokora T; Foster TS; Mould JF
Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):505-23. PubMed ID: 22971036
[TBL] [Abstract][Full Text] [Related]
6. Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in the Netherlands.
Al MJ; Maniadakis N; Grijseels EW; Janssen M
Value Health; 2008; 11(4):589-99. PubMed ID: 18194404
[TBL] [Abstract][Full Text] [Related]
7. Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents.
You JH; Lee KK; Chan TY; Lau WH; Chan FK
Aliment Pharmacol Ther; 2002 Dec; 16(12):2089-96. PubMed ID: 12452942
[TBL] [Abstract][Full Text] [Related]
8. An economic model of long-term use of celecoxib in patients with osteoarthritis.
Loyd M; Rublee D; Jacobs P
BMC Gastroenterol; 2007 Jul; 7():25. PubMed ID: 17610716
[TBL] [Abstract][Full Text] [Related]
9. An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada.
Zabinski RA; Burke TA; Johnson J; Lavoie F; Fitzsimon C; Tretiak R; Chancellor JV
Pharmacoeconomics; 2001; 19 Suppl 1():49-58. PubMed ID: 11280105
[TBL] [Abstract][Full Text] [Related]
10. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
Maetzel A; Krahn M; Naglie G
Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
[TBL] [Abstract][Full Text] [Related]
11. A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model.
Brereton N; Pennington B; Ekelund M; Akehurst R
J Med Econ; 2014 Sep; 17(9):677-84. PubMed ID: 24914585
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland.
Chancellor JV; Hunsche E; de Cruz E; Sarasin FP
Pharmacoeconomics; 2001; 19 Suppl 1():59-75. PubMed ID: 11280106
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.
Moore A; Phillips C; Hunsche E; Pellissier J; Crespi S
Pharmacoeconomics; 2004; 22(10):643-60. PubMed ID: 15244490
[TBL] [Abstract][Full Text] [Related]
14. An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis.
Schnitzer TJ; Kong SX; Mitchell JH; Mavros P; Watson DJ; Pellissier JM; Straus WL
Clin Ther; 2003 Dec; 25(12):3162-72. PubMed ID: 14749154
[TBL] [Abstract][Full Text] [Related]
15. [Cost-effectiveness analysis of the use of celecoxib for the treatment of osteoarthritis].
Moreno A; Vargas E; Soto J; Rejas J
Gac Sanit; 2003; 17(1):27-36. PubMed ID: 12605743
[TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib?
Rahme E; Hunsche E; Toubouti Y; Chabot I
Arthritis Rheum; 2006 Feb; 55(1):27-34. PubMed ID: 16463408
[TBL] [Abstract][Full Text] [Related]
17. Drug utilization review of celecoxib in Ontario.
LeLorier J; Fitzsimon C; Keresteci M; Stewart D; Lavoie F
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii11-6. PubMed ID: 14585913
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK; an update to the NICE model using data from the CONDOR trial.
Brereton N; Winn B; Akehurst R
J Med Econ; 2012; 15(3):465-72. PubMed ID: 22260652
[TBL] [Abstract][Full Text] [Related]
19. [Cost-effectiveness analysis of celecoxib versus non-selective non-steroidal anti-inflammatory drug therapy for the treatment of osteoarthritis in Spain: A current perspective].
De Lossada A; Oteo-Álvaro Á; Giménez S; Oyagüez I; Rejas J
Semergen; 2016; 42(4):235-43. PubMed ID: 26006311
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis.
Jansen JP; Gaugris S; Choy EH; Ostor A; Nash JT; Stam W
Pharmacoeconomics; 2010; 28(4):323-44. PubMed ID: 20222755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
